Merck partnership accelerates needle-free vaccine delivery

October 9, 2012

A University of Queensland invention that will deliver vaccines without the need for needles has struck a significant partnership with US-based pharmaceutical giant Merck, announced today.

The Nanopatch technology, which aims to replace the traditional needle and with a patch smaller than a postage stamp to deliver vaccines painlessly and more efficiently, will be licenced to Merck to begin commercial production on a vaccine.

UQ Vice-Chancellor Professor Peter Høj said the partnership accelerated the process of delivering the revolutionary health technology to people throughout the world.

"A major vaccine maker has looked at technologies around the world and chosen the UQ-invented Nanopatch," Professor Høj said.

"That is a tremendous credit to the team of researchers who developed the technology, led by Professor Mark Kendall.

"It also reflects the excellence of UQ's research , which ensures that practical, life-enhancing discoveries are made accessible to the people who need them.

"This link-up with Merck is especially inspiring, because it may lead to the relief of serious , particularly in remote and developing regions.

"In the immediate term, it will employ more people in Brisbane's innovation economy, and boost the global reputation of Queensland and Australian R&D."

The Nanopatch technology, now being developed by privately held biotechnology company Vaxxas, originated from Vaxxas Chief Technology Officer Professor Mark Kendall's research group at UQ's Australian Institute for Bioengineering and Nanotechnology.

"It is exciting to commence this important partnership between Vaxxas and Merck – a big step forward towards the Nanopatch becoming a vaccine delivery product," Professor Kendall said.

"This directly builds upon intensive and outstanding research on the Nanopatch – conducted by my research group at UQ – taking the Nanopatch from an idea to achieving unprecedented immune responses in animals. And our research has been supported by competitive research grants from both the Australian and Queensland State Governments."

Through the Merck partnership, Vaxxas will be eligible to receive payments for up to two additional vaccines developed by Merck using the Nanopatch platform, as well as milestone payments on Merck vaccine development and regulatory approvals, and royalties on sales of any vaccines that ultimately use the Nanopatch platform.

The Nanopatch works through thousands of small projections designed to deliver a to abundant immune cells in the skin, whereas the traditional syringe delivers to the muscle, where there are few immune cells.

Nanopatch delivery can improve the efficiency of vaccines—including achieving protection against influenza—with only 1/100th of the dose used with a needle and syringe.

The Nanopatch has the potential to improve patient convenience, reduce needle-stick injuries and overcome cross contamination.

It is designed for thermostability and may not need refrigeration, potentially making transport much cheaper and easier, particularly to developing nations.

Related Stories

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.